Category: News

Einstein Hosts Inaugural Therapeutics Venture and Pitch Competition The following excerpt was taken from Einsteinmed.edu — continue reading here. Scientists, venture investment firm leaders, and industry stakeholders gathered on Tuesday, June 7 to attend Albert Einstein College… June 27, 2022—(BRONX, NY)—Scientists, venture investment firm leaders, and industry stakeholders gathered on Tuesday, June 7 to attend

The University of Pittsburgh and Orange Grove Bio Establish Partnership… The following excerpt was taken from Globe Newswire — continue reading here. Orange Grove Bio, a preclinical drug investment and development firm, today announced several key leadership appointments highlighted by its naming John C. Byrd, M.D. Orange Grove Bio, a preclinical drug investment and development

Orange Grove Bio, a preclinical drug investment and development firm, and Cincinnati

1819 Innovation Hub tenant inks key partnership with Korea VC firm The following excerpt was taken from TechOhio– continue reading here. A biotech firm that moved its headquarters from New York to Cincinnati in late 2021 has announced its first major collaboration A biotech firm that moved its headquarters from New York to Cincinnati in

Orange Grove Bio, a USA-based pre-clinical drug investment and development firm, and SV Investment, a South Korea-based venture capital and private equity firm, today announced the establishment of a new partnership through which the companies will collaborate on jointly sourcing and developing novel therapeutics in the USA and Korea. As priority partners, the companies will cultivate the US and Korean biotech landscape through technology licensing and company creation in their respective geographic areas.
Under terms of the partnership, SV Investment will leverage its relationships with biotech companies and academic institutions in Korea to identify licensing opportunities for promising early-stage research in the area of drug development. As part of the agreement, Marc Appel, chief executive of Orange Grove, will join SV Investment as a venture partner and will play a key role in evaluating the licensing opportunities that are identified at Korean biotech companies and universities. As appropriate, Orange Grove will work to license these technologies as a basis for life science company creation in the USA, with SV Investment serving as an early-stage investor in the companies.

New Partnership Continues Pitt’s Turn Toward Commercializing Research The following excerpt was taken from Pittsburgh Post-Gazette — continue reading here. An Ohio drug investment and development firm is partnering with the University of Pittsburgh to commercialize therapies “An Ohio drug investment and development firm is partnering with the University of Pittsburgh to commercialize therapies targeting

The University of Pittsburgh and Orange Grove Bio Establish Partnership… The following excerpt was taken from Globe Newswire — continue reading here. Orange Grove Bio, a preclinical drug investment and development firm, and the University of Pittsburgh today announced the establishment of a collaboration “Orange Grove Bio, a preclinical drug investment and development firm, and

Orange Grove Bio Establishes Partnership with Albert Einstein College of Medicine The following excerpt was taken from Globe Newswire — continue reading here. Orange Grove Bio, AlleyCorp and Alexandria Venture Investments, three industry leaders dedicated to the acceleration and growth “Orange Grove Bio, AlleyCorp and Alexandria Venture Investments, three industry leaders dedicated to the acceleration